Literature DB >> 22459047

RNA-mediated neurodegeneration in fragile X-associated tremor/ataxia syndrome.

Yujing Li1, Peng Jin.   

Abstract

Carriers of fragile X syndrome (FXS) have FMR1 alleles, called premutations, with a number of 5'-untranslated-CGG repeats somewhere between patients, who have over 200 repeats, and normal individuals, with fewer than 60 repeats. Fragile X-associated tremor/ataxia syndrome (FXTAS), a late-onset neurodegenerative disorder, has been recognized in older male fragile X premutation carriers, and FXTAS is uncoupled from the neurodevelopmental disorder, FXS. Several lines of evidence have led to the proposal of an RNA (fragile X premutation rCGG repeat)-mediated gain-of-function toxicity model for FXTAS, in which rCGG repeat-binding proteins (RBPs) could become functionally limited by their sequestration to lengthy rCGG repeats. In this review, we will discuss the recent progress towards understanding the molecular basis of RNA-mediated neurodegeneration in FXTAS. This article is part of a Special Issue entitled: RNA-Binding Proteins.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22459047      PMCID: PMC3372578          DOI: 10.1016/j.brainres.2012.02.057

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  48 in total

1.  FTD and ALS: genetic ties that bind.

Authors:  Harry T Orr
Journal:  Neuron       Date:  2011-10-20       Impact factor: 17.173

2.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 3.  RNA-mediated neurodegeneration in repeat expansion disorders.

Authors:  Peter K Todd; Henry L Paulson
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

4.  Retrotransposon activation contributes to fragile X premutation rCGG-mediated neurodegeneration.

Authors:  Huiping Tan; Abrar Qurashi; Mickael Poidevin; David L Nelson; He Li; Peng Jin
Journal:  Hum Mol Genet       Date:  2011-09-22       Impact factor: 6.150

5.  CGG-repeat length threshold for FMR1 RNA pathogenesis in a cellular model for FXTAS.

Authors:  Gry Hoem; Christopher R Raske; Dolores Garcia-Arocena; Flora Tassone; Eleonora Sanchez; Anna L Ludwig; Christine K Iwahashi; Madhur Kumar; Jane E Yang; Paul J Hagerman
Journal:  Hum Mol Genet       Date:  2011-03-09       Impact factor: 6.150

6.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 7.  Drosophila melanogaster in the study of human neurodegeneration.

Authors:  Frank Hirth
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-08       Impact factor: 4.388

8.  Spatial code recognition in neuronal RNA targeting: role of RNA-hnRNP A2 interactions.

Authors:  Ilham A Muslimov; Mihir V Patel; Arthur Rose; Henri Tiedge
Journal:  J Cell Biol       Date:  2011-08-01       Impact factor: 10.539

9.  Nuclear accumulation of stress response mRNAs contributes to the neurodegeneration caused by Fragile X premutation rCGG repeats.

Authors:  Abrar Qurashi; Wendi Li; Jian-Ying Zhou; Junmin Peng; Peng Jin
Journal:  PLoS Genet       Date:  2011-06-02       Impact factor: 5.917

Review 10.  Maintaining the brain: insight into human neurodegeneration from Drosophila melanogaster mutants.

Authors:  Derek Lessing; Nancy M Bonini
Journal:  Nat Rev Genet       Date:  2009-06       Impact factor: 53.242

View more
  20 in total

Review 1.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

Review 2.  Fragile X-associated tremor/ataxia syndrome.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Ann N Y Acad Sci       Date:  2015-01-26       Impact factor: 5.691

3.  Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects.

Authors:  Jason W Hoskins; Leslie O Ofori; Catherine Z Chen; Amit Kumar; Krzysztof Sobczak; Masayuki Nakamori; Noel Southall; Samarjit Patnaik; Juan J Marugan; Wei Zheng; Christopher P Austin; Matthew D Disney; Benjamin L Miller; Charles A Thornton
Journal:  Nucleic Acids Res       Date:  2014-05-05       Impact factor: 16.971

4.  CGG repeats in RNA modulate expression of TDP-43 in mouse and fly models of fragile X tremor ataxia syndrome.

Authors:  Jocelyn N Galloway; Chad Shaw; Peng Yu; Deena Parghi; Mickael Poidevin; Peng Jin; David L Nelson
Journal:  Hum Mol Genet       Date:  2014-06-30       Impact factor: 6.150

Review 5.  Pharmacotherapy for Fragile X Syndrome: Progress to Date.

Authors:  Matthew H Davenport; Tori L Schaefer; Katherine J Friedmann; Sarah E Fitzpatrick; Craig A Erickson
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

6.  Characterization and Early Detection of Balance Deficits in Fragile X Premutation Carriers With and Without Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS).

Authors:  Joan A O'Keefe; Erin Robertson-Dick; Emily J Dunn; Yan Li; Youping Deng; Amber N Fiutko; Elizabeth Berry-Kravis; Deborah A Hall
Journal:  Cerebellum       Date:  2015-12       Impact factor: 3.847

7.  Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice.

Authors:  Adam J Iliff; Abigail J Renoux; Amy Krans; Karen Usdin; Michael A Sutton; Peter K Todd
Journal:  Hum Mol Genet       Date:  2012-12-18       Impact factor: 6.150

Review 8.  Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome.

Authors:  Randi Hagerman; Paul Hagerman
Journal:  Lancet Neurol       Date:  2013-08       Impact factor: 44.182

Review 9.  RNA-binding protein misregulation in microsatellite expansion disorders.

Authors:  Marianne Goodwin; Maurice S Swanson
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

10.  The Rpe65 rd12 allele exerts a semidominant negative effect on vision in mice.

Authors:  Charles B Wright; Micah A Chrenek; Wei Feng; Shannon E Getz; Todd Duncan; Machelle T Pardue; Yue Feng; T Michael Redmond; Jeffrey H Boatright; John M Nickerson
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-17       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.